AccScience Publishing / CP / Online First / DOI: 10.36922/CP026360058
Cite this article
2
Download
35
Views
Related Info Links
More by Authors Links
Journal Browser
Volume | Year
Issue
Search
News and Announcements
View All
ORIGINAL RESEARCH ARTICLE

Differential effect of obesity on cervical neoplastic progression and human papillomavirus persistence: A retrospective cohort study

Cem Yagmur Ozdemir1* ,  Nayif Cicekli2 ,  Cevdet Doğu3 ,  Dagistan Tolga Arioz4
Show Less
1 Department of Gynecological Oncology, Afyonkarahisar State Hospital, Afyonkarahisar , Türkiye
2 Department of Gynecological Oncology, Erzurum City Hospital, Erzurum , Türkiye
3 Department of Gynecology and Obstetrics, Afyonkarahisar State Hospital, Afyonkarahisar , Türkiye
4 Department of Gynecological Oncology, Faculty of Medicine, Afyonkarahisar Health Sciences University, Afyonkarahisar , Türkiye
Received: 31 August 2026 | Revised: 27 September 2026 | Accepted: 15 October 2026 | Published online: 18 November 2026
© 2026 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Abstract

The role of obesity in human papillomavirus (HPV) persistence and the development of cervical neoplasia remains incompletely understood. This study evaluates the independent effects of obesity, smoking, and age on high-risk HPV persistence and the development of high-grade cervical lesions (cervical intraepithelial neoplasia [CIN]2+), and assesses whether obesity improves prediction of CIN2+. This retrospective cohort study included 445 women who underwent high-risk HPV testing between December 2023 and December 2025. HPV persistence was defined as detection of the same HPV genotype in at least two consecutive tests performed ≥ 12 months apart. Body mass index was categorized as non-obese (<30 kg/m2) or obese (≥30 kg/m2). Multivariable logistic regression analyses were performed to identify independent determinants of HPV persistence and CIN2+. Receiver operating characteristic curve analysis was used to compare a baseline model including age and smoking with an extended model additionally including obesity. Persistent HPV infection was identified in 59 women (13.3%). Smoking was a strong independent predictor of HPV persistence (adjusted odds ratio [aOR]: 13.07; 95% confidence interval [CI]: 6.54–26.09; p < 0.001), and increasing age was also independently associated with persistence (aOR: 1.04 per year; 95% CI: 1.01–1.07; p = 0.023). Obesity was not independently associated with HPV persistence. CIN2+ was detected in 95 women (21.3%). Obesity was independently associated with CIN2+ (aOR: 1.96; 95% CI: 1.14–3.38; p = 0.015), whereas smoking and age were not significant predictors. The addition of obesity modestly improved discrimination for CIN2+ prediction (area under the curve [AUC] 0.545 vs. 0.587). Smoking and age are key determinants of HPV persistence, whereas obesity appears to be associated primarily with cervical neoplastic progression rather than viral persistence. The modest increase in AUC suggests limited but measurable predictive contribution of obesity to CIN2+ risk.

Keywords
Human papillomavirus
Human papillomavirus persistence
Obesity
Smoking
Age
Funding
None.
Conflict of interest
The authors declare no conflict of interest.
References
  1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–263. doi: 10.3322/caac.21834.
  2. Kou Y, Tang X, Liang D, et al. HPV genotypes in invasive cervical cancer: prevalence, risk attribution, and optimized vaccine strategies in western China. Front Public Health. 2024;12:1455931. doi: 10.3389/fpubh.2024.1455931
  3. McBride AA. Human papillomaviruses: diversity, infection and host interactions. Nat Rev Microbiol. 2022;20(2):95-108. doi: 10.1038/s41579-021-00617-5
  4. Wolf J, Kist LF, Pereira SB, et al. Human papillomavirus infection: epidemiology, biology, host interactions, cancer development, prevention, and therapeutics. Rev Med Virol. 2024;34(3):e2537. doi: 10.1002/rmv.2537
  5. Agrati C, Bartolini B, Bordoni V, et al. Emerging viral infections in immunocompromised patients: a great challenge to better define the role of immune response. Front Immunol. 2023;14:1147871. doi: 10.3389/fimmu.2023.1147871
  6. Majeed K, Ali H. Association of low-grade inflammation and oxidative stress with metabolic dysfunction in healthy obese individuals. AIMS Allergy Immunol. 2025;9(2):56-69. doi: 10.3934/allergy.2025004
  7. Tilg H, Ianiro G, Gasbarrini A, Adolph TE. Adipokines: masterminds of metabolic inflammation. Nat Rev Immunol. 2025;25(4):250-265. doi: 10.1038/s41577-024-01103-8
  8. Kim JW, Kim JH, Lee YJ. The role of adipokines in tumor progression and its association with obesity. Biomedicines. 2024;12(1):97. doi: 10.3390/biomedicines12010097
  9. Gilani A, Stoll L, Homan EA, Lo JC. Adipose signals regulating distal organ health and disease. Diabetes. 2024;73(2):169-177. doi: 10.2337/dbi23-0005
  10. Shaikh SR, Beck MA, Alwarawrah Y, MacIver NJ. Emerging mechanisms of obesity-associated immune dysfunction. Nat Rev Endocrinol. 2024;20(3):136-148. doi: 10.1038/s41574-023-00932-2
  11. Sultana A, Rana S. Mechanisms underlying obesity-malignancy connection: a systematic narrative review. J Physiol Biochem. 2025;81(2):403-439. doi: 10.1007/s13105-025-01084-9
  12. De Sanctis JB, Balda Noria G, García AH. Exploring how adipose tissue, obesity, and gender influence the immune response to vaccines: a comprehensive narrative review. Int J Mol Sci. 2025;26(2):862. doi: 10.3390/ijms26020862
  13. Kajabwangu R, Izudi J, Bazira J, Ssedyabane F, Turanzomwe S, Birungi A, et al. Effect of metabolic syndrome and its components on the risk and prognosis of cervical cancer: A literature review. Gynecol Oncol Rep. 2024;54:101438. doi: 10.1016/j.gore.2024.101438
  14. Zhao R, Sekar P, Bennis SL, Kulasingam S. A systematic review of the association between smoking exposure and HPV-related cervical cell abnormality among women living with HIV: implications for prevention strategies. Prev Med. 2023;170:107494. doi: 10.1016/j.ypmed.2023.107494
  15. World Health Organization. Obesity and overweight. Updated October 7, 2026. Accessed August 7, 2026. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
  16. Thakral A, Lee JJ, Hou T, et al. Smoking and alcohol by HPV status in head and neck cancer: a Mendelian randomization study. Nat Commun. 2024;15(1):7835. doi: 10.1038/s41467-024-51679-x
  17. Patra S, Shand H, Ghosal S, Ghorai S. HPV and male cancer: pathogenesis, prevention and impact. J Oman Med Assoc. 2025;2(1):4. doi: 10.3390/joma2010004
  18. Tsima BM, Motlhatlhedi K, Sharma K, et al. The association between smoking and cervical human papillomavirus infection among women from indigenous communities in western Botswana. PLoS ONE. 2024;19(6):e0302153. doi: 10.1371/journal.pone.0302153
  19. Urbute A, Thomsen LT, Belmonte F, Kesmodel US, Frederiksen K, Kjaer SK. The role of body mass index in incidence and persistence of cervical human papillomavirus infection. Ann Epidemiol. 2020;49:36-41. doi: 10.1016/j.annepidem.2020.07.011
  20. Liu SH, Chen HJ, Hsieh TH, et al. Excessive adiposity, metabolic health, and risks for genital human papillomavirus infection in adult women: a population-based cross-sectional study. BMC Obes. 2015;2(1):39. doi: 10.1186/s40608-015-0071-3
  21. Huang X, Zhao Q, Yang P, et al. Metabolic syndrome and risk of cervical human papillomavirus incident and persistent infection. Medicine. 2016;95(9):e2905. doi: 10.1097/MD.0000000000002905
  22. Ma K, Li S, Wu S, Zhu J, Yang Y. Impact of smoking exposure on human papillomavirus clearance among Chinese women: A follow-up propensity score matching study. Tob Induc Dis. 2023;21(March):1-11. doi: 10.18332/tid/161026
  23. Zhao M, Kang P, Zhu L, et al. Global pattern of persistent human papillomavirus infection in female genital tract: An update system review and meta-analysis. iScience. 2024;27(10):110991. doi: 10.1016/j.isci.2024.110991
Share
Back to top
Cancer Plus, Electronic ISSN: 2661-3840 Print ISSN: 2661-3832, Published by AccScience Publishing